QNRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Quoin Pharmaceuticals Ltd (QNRX) is not a strong buy for a beginner, long-term investor at this time. The stock lacks clear positive momentum, has weak financial performance, and no significant catalysts to drive growth in the near term. It is better to hold off on investing until there are stronger signals or improvements in financial and market conditions.
The stock shows bearish moving averages (SMA_200 > SMA_20 > SMA_5), indicating a downward trend. The RSI is neutral at 29.831, and the MACD is positive but contracting. Key support is at 5.62, and resistance is at 6.774. Overall, the technical indicators suggest a weak and uncertain trend.
Alliance Global raised the price target to $35 from $25, indicating potential long-term optimism. However, this is based on a sum-of-the-parts analysis and priority review vouchers.
No recent news or significant trading trends from hedge funds or insiders. Financial performance remains weak with negative net income and EPS. The stock has a low probability of significant short-term gains based on candlestick pattern analysis.
In Q4 2025, revenue remained at 0 with no growth. Net income improved by 88.14% YoY but is still negative at -$4,348,373. EPS dropped significantly by -86.01% YoY to -1.73. Gross margin remains at 0. Overall, the financials are weak and do not indicate growth potential.
Alliance Global maintains a Buy rating and raised the price target to $35 from $25, citing higher valuation on priority review vouchers. However, this optimism is not supported by recent financial or market trends.
